MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced its upcoming inclusion in the Russell 3000® Index and the Russell 2000® Index following the annual reconstitution of the Russell indexes. This change will take effect after the U.S. markets open on June 30, 2025.
The Russell indexes, maintained by global provider FTSE Russell, are a key benchmark for investment managers and institutional investors. They are used to track market performance through index funds and active investment strategies. The Russell 3000® Index comprises the 3,000 largest public U.S. companies by market capitalization, while the Russell 2000® Index focuses specifically on small-cap companies. Inclusion in these indexes is determined annually based on market-cap rankings and style attributes, with the 2025 reconstitution based on data as of April 30.
“This inclusion in the Russell 3000® and Russell 2000® Indexes represents an important validation of our strategic vision and operational execution,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics.
Expanding Access to Mental Health Treatment
Neuronetics’ signature NeuroStar Advanced Therapy, a transcranial magnetic stimulation (TMS) technology, has positioned the company as a pioneer in innovative mental health treatments. Recently, the company has expanded its footprint through its Greenbrook clinic network, aiming to increase access to advanced mental health solutions.
“As we continue expanding access to innovative mental health treatments through our integrated approach—combining our leading NeuroStar technology with our growing Greenbrook clinic network—this milestone enhances our visibility among institutional investors and reflects the significant progress we’ve made in transforming how mental healthcare is delivered,” Sullivan added.
Financial Strength and Market Momentum
With approximately $10.6 trillion in assets benchmarked against the Russell indexes as of June 2024, inclusion in these benchmarks is expected to draw greater attention from institutional investors. Neuronetics also noted its focus on achieving positive cash flow and driving growth across its business model.
“With our path to positive cash flow this year and our proven operating model driving strong growth, we’re well-positioned to continue delivering value for both patients and shareholders,” Sullivan stated.
A Milestone for Growth
Neuronetics’ inclusion in the Russell indexes signifies broader recognition of its market position and underscores the company’s growth momentum. By joining both the Russell 3000® and Russell 2000® Indexes, the company is poised to strengthen its relationship with institutional investors while advancing its mission to revolutionize mental health care.
This development marks an important step forward for Neuronetics as it continues to implement its strategic initiatives and reshape the standard for mental health treatment.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.